Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-BN-EBV
- Development stage
- Phase 1
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-BN-EBV is a recombinant, replication-incompetent Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vector-based vaccine developed by Bavarian Nordic for the prevention and treatment of Epstein-Barr virus (EBV) infection. The vaccine is engineered to express multiple EBV antigens, including the envelope glycoproteins gp350, gH, and gL, which are essential for viral entry into B cells and epithelial cells, as well as T-cell antigens BZLF1, BRLF1 (as a BZLF1-BRLF1 fusion protein), and EBNA-3A. By targeting both humoral (neutralizing antibodies) and cellular (T-cell) immune responses, MVA-BN-EBV aims to provide comprehensive protection against EBV infection and associated diseases, such as infectious mononucleosis and EBV-related malignancies. It is currently being evaluated in Phase 1 clinical trials.
- Other names
- MVA-BN-EBV vaccinerecombinant MVA-BN-EBV vaccine
02
Targets
BZLF1 (Epstein-Barr virus replication and transcription activator)EBNA-3A (Epstein-Barr virus nuclear antigen 3A)MHC I (MHC class I})GH (Growth hormone)gp350 (Epstein-Barr virus glycoprotein 350)gL (Epstein-Barr virus glycoprotein L)
Beyond the preview
Go deeper on MVA-BN-EBV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-BN-EBV.